Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Eisai

Status: Completed

Conditions: Thyroid Neoplasms

Treatments: Drug: Lenvatinib

Study type: Observational

Funder types: Industry

Identifiers

NCT02430714

LEN01T

Details and patient eligibility

About

This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.

Enrollment: 629 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. All participants with unresectable thyroid cancer and administrated Lenvatinib.

Trial design

629 participants in 1 patient group

Arm 1

Description:

A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.

Treatment:

Drug: Lenvatinib